Stocks and Investing Stocks and Investing
Mon, October 29, 2018
Fri, October 26, 2018

Andrew Fein Upgraded (VRTX) to Strong Buy and Held Target at $220 on, Oct 26th, 2018


Published on 2024-10-26 09:59:39 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Strong Buy and Held Target at $220 on, Oct 26th, 2018.

Andrew has made no other calls on VRTX in the last 4 months.



There are 5 other peers that have a rating on VRTX. Out of the 5 peers that are also analyzing VRTX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Maintained at Hold with Increased Target to $188 on, Thursday, July 26th, 2018


These are the ratings of the 4 analyists that currently disagree with Andrew


  • Christopher Raymond of "Raymond James" Maintained at Buy with Decreased Target to $201 on, Thursday, October 25th, 2018
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $192 on, Thursday, October 25th, 2018
  • Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $206 on, Monday, July 30th, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $211 on, Thursday, July 26th, 2018
Contributing Sources